Introduction
The role of idiopathic respiratory distress syndrome (IRDS) in perinatal death is proved by data published in various countries [7, 9, 10, 24, 26, 27] . In view of the high incidence of premature births in Hungary as well as observations that it is premature birth above all which predisposes the development of IRDS, steroid prophylaxis remains in the center of professional interest [14, 16, 22, 26, 27] , As numerous side effects and risks for steroid administration is known [10, 18] , other possibilities should be investigated for preventive medication. Wu et al. [29, 30] with laboratory animal experiments, MACHIACH et al. [11, 12, 21] in human subjects proved that other pharmacologic agents can be used. Intraamniotically administered thyroxin beneficially influences the development of pulmonary surfactant, and it is applicable for preventing IRDS. Since 1974 we have regularly used dexamethasone for IRDS prophylaxis; thus, we have had the opportunity to observe that in pregnancy complicated by toxemia, intrauterine death was more frequent following steroid prophylaxis. It seemed reasonable that for IRDS prophylaxis, thyroxin should be administered intraamniotically in pregnancy complicated by preeclamptic toxemia. Our purpose is to report our observations on the effects of intraamniotically applied L-Thyroxin "Henning".
Material and method
Between January 1, 1982 and January 1, 1984 according to WITTLINGER, 18 cases of serious and fairly serious toxemic pregnancy were administered 500 g of L-Thyroxin "Henning" in a single dose intraamniotically after the laboratory findings of negative pulmonary maturity in the amniotic fluid. The ages of the patients were between 16 and 39 years with a gestational age of 29-40 weeks (mean: 36.3 weeks). Prior to the considered therapy but after the thorough clinical examinations of the mother, amniotic fluid was obtained by ultrasound-directed transabdominal amniocentesis with a PICKER LS 2700 ultrasound machine. After obtaining 30ml of amniotic fluid, the needle was left in place with sterile closing. For rapid determination, a Clements test was performed, and in case it showed pulmonary immaturity, via the same needle, 500 μg of L-Thyroxin "Henning" was injected into the amnionic fluid. Removing the needle, the patient was kept under surveillance for 24 hours. Prior to thyroxin treatment, cholesterin test was made from cubital vein and the level of estriol, HPL, as well as Ts and T4 were determined by Ria method. The same parameters were examined 1 hour after thyroxin administration as well as every 24 hour interval up to parturition. After delivery, the same parameters were determined as well as the level of Ts and T4 from mixed blood from the umbilical cord. Besides the Clements test, as part of amniotic fluid analysis, the L/S ratio, amniocrit, glucose, creatinine, estriol and HPL values were determined. In every case the bacteriological examination of the amniotic fluid was performed. Forty-eight hours after medication the amniocentesis was repeated and the chosen parameters rechecked. When medically indicated, labor was induced. When the maternal/fetal state did not require induction, we awaited the onset of spontaneous labor while performing intrauterine examinations. After delivery Ts and T4 levels were determined from mixed cord blood.
During the postnatal period, the neonatologist kept the newborn under strict surveillance to observe any early possible side effects. In the 5th day after delivery, from venous blood, the Ts and T4 levels were repeated by Ria method. It was not possible to measure Ts levels from amniotic fluid because a precipitate was not obtainable from the tube. The changes of the T4 level and the L/S ratio in the amniotic fluid as well as that of T4 in the cord were statistically analyzed by Student's x 2 -test.
Results
The effect of the intraamniotically administered thyroxin on the various parameters examined is presented in table I. 48 hours after thyroxin administration, the T4 level of the amniotic fluid showed an increase of extreme degree; the difference was very significant (p < 0.001). The maternal Ts and T4 levels did not change due to the medication (figure 1).
When the delivery occured 48 hours after medication, the T4 level gradually decreased in the amniotic fluid, and 5 -6 days after thyroxin administration the T4 levels practically showed the prior value. Forty-eight hours after thyroxin administration the L/S ratio rose more then two times in each case (figure 2).
The T4 level in the cord blood taken after delivery, increased compared to the basic value but the difference was not significant (p > 0.05). This may be explained by the fact that the majority of deliveries occured several days after medication. The level of newborn venous blood was also normal in the 5th postnatal day showing euthyreoid values. During neonatal intensive surveillance, no change was observed that could have been due to thyroxin effect.
In the period of investigation, 1584 deliveries were performed, 58 of which were serious and fairly serious toxemic pregnancies as defined by WITTLINGER. Thyroxin was not given in 40 cases for the following reasons: contraindication, premature rupture of membrane, fetal distress, intrauterine death and also when the test of amniotic fluid demonstrated fetal pulmonary maturity. These 40 cases were regarded as the nontreated group. The data obtained from the thyroxin treated group and the non-treated group are presented in table II. Although 7 of the 18 thyroxin treated pregnant women were delivered of premature infants, IRDS of HMB was not observed. Among the premature infants of the 40 toxemic pregnant women, who were not treated with thyroxin, IRDS was observed in 8 cases, and 2 of the infants were under 1500g and died. In both cases the autopsy findings demonstrated hyaline membrane disease (in one of the two the direct cause being intracranial hemorrhage). In this thyroxin-non-treated group 5 additional infants were lost. ,.,. . . ... , ., . . . ,. Five mtrauterme deaths prior to delivery were due to toxemic placenta] msufficiency accord\mg to the autopsy findings. The gravida was in the 33rd gestational week was hospitalized with the diagnosis of preeclamptic toxemia. The delivery was induced because her blood pressure was 180-190/130 torr despite medication. Her proteiunuria was rapidly progressing (to 28.7 g/day) in the collected urine, and in addition the estriol level was too low for measurement. An amniocentesis was performed before the induction and indicated pulmonary immaturity (Clements test: negative, L/S ratio: 1.2, amniocrit: 0.20, S «βΑΪΑΑ ES after the medication, her temperature rose and intrauterine death occurred. The fetus weighed 2100 g, and the autopsy could demonstrate only symptoms of intrauterlar weight (TBG) cannot pass through the placental barrier. The level of maternal T4 can influence that of the fetal's only in early pregnancy (under 18 weeks). He also proved that the T4 reaches the fetus via the amniotic fluid. The T4 level of the amniotic fluid can be measured and its changes follow those from the fetal serum level. It was also established that in the fetus, the thyroid hormones favorably influence the growth of the bone structure, the development of the nervous system, the myeliriization and increase the production of pulmonary surfactant in the II type pneumocytes [ . . , ι · t u increased the pulmonary surfactant level m laboratory animals. The action of mechanism presumably takes effect by accelerating the differentiation of a certain enzymetic system. Observations on patients are not unanimous. Intraamniotically administered T4 is used not only for JRDS prevention but also f or other tfiera-
-WEINER et al. [28] attempted to treat proved fetal goiter in the 30th gestational week by intraamniotically applied T4. SCHREIER et al. no] could not observe a decressed incidence of »Ι« «ft« intraaomiotically administered T,. MACHIACH et al. [11, 12] reported Significantly decreasing incidence of IRDS following intraamniotically administered T4. DUDENHAUSEN
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administration the lecithin level m the amniotic fluid significantly increased and, parallel witĥ s ' ^e °^s ervec^ number of hyaline membrane syndrome decreased. However, in the 22 cases The dangers of preeclamptic toxemia both for examined, on five occasions fetal tachycardia the mother and the fetus are well known [2, 4, could be observed 2 days after the thyroxin 18, 23] . One of the most effective means of administration. In 1982 we reported [13, 25] preventing complications is an induced preterm favorable results obtained in a few cases; thus delivery. The greatest danger of a poorly timed the drug has been used in a larger number of preterm delivery is IRDS, due to pulmonary cases. On the basis of our results it is concluded immaturity. In cases of serious toxemia, after that thyroxin, in the applied dose, brings about steroid administration, the number of intrauter-within 48 hours, an increase in the L/S ratio as ine deaths rise [2, 10, 18] . In recent years more well as the Clements test used for determinaauthors reported that thyroxin stimulated the tions of pulmonary surfactant. The other parasurfactant production. The role of Ts and T4 meters examined in the amniotic fluid, repin fetal development has not been cleared up resenting functional and somatic maturity, and including the physiology. NIVELON [15] pointed the hormone estriol, HPL levels indicating the out that T4 bound to a protein of great molecu-intrauterine state of the fetus, did not change due to thyroxin. Neither in the mother nor in the newborn was clinical side effect observed due to thyroxin prophylaxis. The T4 was rapidly eliminated from the amniotic fluid. The postmedication T4 level in the fetus was gradually decreased depending on the time that elapsed until delivery, and on the 5th to 6th days following the thyroxin administration it was almost normal. On the post-natal 5th day, the T4 levels of the venous blood taken from the newborn infants did not show any increase. The passage of the drug via amniotic fluid to the fetus presumably stops at the placenta barrier and the thyroxin does not reach the mother. This presumption is supported by the fact that an increased thyroxin level was not observed in the maternal venous blood regardless of the time of administration. The placenta serves as a twoway barrier (mother-fetus, fetus-mother) for the drug. This is supported by our observation that following the intraamniotically administered 500 g L-Thyroxin, the maternal levels were not altered. In our opinion, in cases of serious and fairly serious preeclamptic toxemia, where the induction of labor is vital, in the interest of the fetus, intraamniotically administered LThyroxin can be effectively applied, though a premature birth can be inevitable.
Summary
In 18 cases of serious and fairly serious toxemic pregnancy, the authors gave 500 § L-Thyroxin "Henning" intraamniotically after the laboratory evaluation demonstrated negative pulmonary maturity from an amniotic fluid sample. Maternal and fetal complications due to the drug could not be observed. Despite a 39% premature incidence, IRDS and hyaline membrane disease were not observed. The administered T4 caused a positive change in the direction of the L/S ratio and the Clements test. The other amniotic fluid parameters did not change, exept the T4 level. The extremly high T4 level obtained 48 hours later gradually became normal several days later. The T4 values obtained from the blood of the mother and the newborn on the 5th postnatal day were normal. In toxemic cases where the induction of labor is vital and there is a risk of IRDS and steroid application in contraindicated, intraamniotic thyroxin is recommended as prophylaxsis for IRDS.
Keywords: Fetal pulmonary maturity, preeclamptic toxemia, thyroxin. Despite more than a century of ever-increasing scientific interest and research, anorexia nervosa -the pathological pursuit of thinness -still presents a challenge to clinicians throughout the world. It has become practically impossible to keep in touch with the constant proliferation of scientific literature on this subject. Moreover, the clinician (the general practitioner, the psychiatrist or the psychologist) needs, first and foremost, practical guidelines for his everyday therapeutic work with these patients.
Therefore, two experienced clinicians, who are daily involved in research and treatment of large numbers of anorexia nervosa patients, decided to write the first book dealing extensively with the many practical issues one is faced with when investigating and treating anorectic patients of all ages and in all stages of their illness. No single treatment modality, psychotherapeutic, pharmacologic or nutritional, has provided the final solution for the management of this intriguing syndrome. Hence, the therapeutic approach described in this book Is characterized as an eclectic, broad spectrufti or multimodal treatment in which strategies and interventions from different therapeutic models have been integrated. 
